You have full access to this article via your institution. Figure 1: A family with multiple GISTs and mutation of the KIT gene.

Advanced SDH-deficient GISTs are usually treated with the same therapies targeting KIT and PDGFRA receptors as those used in metastatic GIST. However, these treatments display less activity in the ...

The tyrosine kinase inhibitor imatinib targets the human KIT receptor and the platelet-derived growth factor receptor-α. This drug exhibits impressive antitumor effects against GIST and has ...

designed to address both primary and secondary KIT mutations in patients with GIST. Early data from the StrateGIST 1 Phase I/Ib trial demonstrated promising antitumor activity, with an objective ...

IDRX-42 has demonstrated activity against all key primary and secondary KIT mutations, designed to improve outcomes for patients with GIST. Updated clinical data from StrateGIST 1, an ongoing ...